SGL Investment Advisors Inc. Purchases 412 Shares of Johnson & Johnson $JNJ

SGL Investment Advisors Inc. grew its position in Johnson & Johnson (NYSE:JNJ) by 1.3% in the second quarter, HoldingsChannel.com reports. The fund owned 32,749 shares of the company’s stock after buying an additional 412 shares during the period. Johnson & Johnson comprises about 2.4% of SGL Investment Advisors Inc.’s portfolio, making the stock its 11th biggest holding. SGL Investment Advisors Inc.’s holdings in Johnson & Johnson were worth $5,102,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. TriaGen Wealth Management LLC boosted its holdings in shares of Johnson & Johnson by 22.3% during the 2nd quarter. TriaGen Wealth Management LLC now owns 5,030 shares of the company’s stock worth $768,000 after buying an additional 917 shares during the period. Joel Isaacson & Co. LLC boosted its holdings in shares of Johnson & Johnson by 1.3% during the 2nd quarter. Joel Isaacson & Co. LLC now owns 75,087 shares of the company’s stock worth $11,469,000 after buying an additional 955 shares during the period. HTG Investment Advisors Inc. boosted its holdings in shares of Johnson & Johnson by 12.1% during the 2nd quarter. HTG Investment Advisors Inc. now owns 1,675 shares of the company’s stock worth $256,000 after buying an additional 181 shares during the period. Sunbeam Capital Management LLC bought a new stake in shares of Johnson & Johnson during the 2nd quarter worth about $240,000. Finally, KLP Kapitalforvaltning AS boosted its holdings in shares of Johnson & Johnson by 3.1% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 1,117,314 shares of the company’s stock worth $170,670,000 after buying an additional 33,700 shares during the period. Institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on JNJ. Bank of America lifted their target price on shares of Johnson & Johnson from $175.00 to $198.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Royal Bank Of Canada lifted their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a report on Thursday, July 17th. The Goldman Sachs Group boosted their price objective on shares of Johnson & Johnson from $185.00 to $186.00 and gave the company a “buy” rating in a report on Friday, September 19th. Wells Fargo & Company set a $212.00 price objective on shares of Johnson & Johnson and gave the company an “overweight” rating in a report on Friday, October 3rd. Finally, UBS Group set a $198.00 price objective on shares of Johnson & Johnson in a report on Friday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $189.88.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $189.75 on Thursday. The firm has a 50 day moving average of $177.49 and a 200-day moving average of $163.37. The stock has a market capitalization of $456.98 billion, a PE ratio of 20.29, a PEG ratio of 2.41 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $190.22.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the previous year, the company earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.